Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Intermittent androgen suppression therapy for prostate cancer

Androgen suppression - the inhibition of testosterone and other male hormones - is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form.

28 Mar 2012

TJUH's Department of Radiation Oncology unveils new brachytherapy suite

Thomas Jefferson University Hospital's Department of Radiation Oncology has unveiled the region's only image-guided brachytherapy suite, where patients can have radiation imaging, planning and treatment in a single location without being moved.

27 Mar 2012

Only few OB-GYNs routinely inquire about patients' sexual issues

How often does your doctor ask about your sexual life? Unfortunately, the answer may be: not often enough. Leaving the subject off the check-up checklist could mean missing an important link to overall wellness.

23 Mar 2012

IBM, MSKCC partner to develop decision support tool for oncologists

Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide medical professionals with improved access to current and comprehensive cancer data and practices.

23 Mar 2012

Blocking PFKFB4 enzyme could prevent growth of prostate cancer cells

Cancer Research UK scientists have discovered how blocking a key enzyme, which helps convert glucose into energy, could provide a new way to kill prostate cancer cells, according to a study published in the journal Cancer Discovery.

23 Mar 2012

PFKFB4 gene leads to excessive growth of prostate cancer cells

Cancer cell metabolism may present a new target for therapy as scientists have uncovered a possible gene that leads to greater growth of prostate cancer cells.

23 Mar 2012

Study demonstrates molecular mechanisms of cadmium-induced prostate cancer

A recent study conducted at Marshall University may eventually help scientists develop new treatments for prostate cancer, the most common malignancy in American men.

22 Mar 2012

Epidemiologist examines effect of population aging on inpatient care

The effect of population aging on the number of admissions to hospital for inpatient treatment is examined by epidemiologist Enno Nowossadeck in the latest issue of Deutsches -rzteblatt International.

20 Mar 2012

Thousands of cancer cases could be prevented by 2025 with better diet & exercise: Australian study

According to new research nearly 43,000 cases of cancer could be prevented in 2025 if Australians eat better and exercised more. Cancer Council researchers estimate about 170,000 cases of cancer will be diagnosed in 2025 - a 60 per cent increase on the number of diagnoses in 2007. The researchers say governments must act to reduce the future burden of cancer.

19 Mar 2012

Prostate Center of Academic Urology receives accreditation from ACR, ASTRO

The Prostate Center of Academic Urology has been awarded a three-year term of accreditation in radiation oncology from the American College of Radiology (ACR) and The American Society for Radiation Oncology.

19 Mar 2012

Researchers report higher price tag for robotic prostatectomy surgery

In perfecting the science of medicine, advancements always face exhaustive scrutiny and opposition. Typically, these rigors focus on confirming the efficacy of a procedure or treatment to ensure it remains in the patient's best interest for healing or wellness. More recently, with heightened emphasis on government-funded healthcare, medical procedures such as robotic prostatectomy surgery for prostate cancer treatment are under fire for cost.

17 Mar 2012

Clinicians to discuss best approaches for future cancer treatment at Brainlab's radiotherapy meeting

Today clinicians from around the world will gather at the 4th Brainlab European Radiotherapy User Meeting to share their best practice and experiences in treating difficult-to-treat cancers using advanced radiotherapy.

17 Mar 2012

OncoGenex prices underwritten public offering of 4,165,000 shares of common stock

OncoGenex Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share.

17 Mar 2012

LCA comments on CDC's new anti-tobacco campaign

Today, Lung Cancer Alliance (LCA) said that the new anti-tobacco campaign just launched by the Centers for Disease Control and Prevention (CDC) is an important revitalization of the efforts to prevent young people from smoking and encourage all who do smoke to quit.

17 Mar 2012

Guidelines for cervical cancer screening revised

The guidelines say that women between 30 and 65 can wait five years between screenings if they get both a Pap test and an HPV test.

16 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Prostate cancer screening debate continues

Routine tests that help detect prostate cancer actually do reduce the risk of death from the disease, researchers said. Screening is done with a simple blood test that measures levels of prostate-specific antigen, or PSA.

15 Mar 2012

MDxHealth fourth quarter total revenues increase 48% to €0.9M

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.

15 Mar 2012

African Americans in Georgia found to have poor survival rates from cancer

African Americans in Georgia, especially in rural areas, have drastically poorer survival rates from cancer. These disparities are much larger when compared to national data, according to the findings from a study recently published in the journal Cancer by a team of researchers in the University of Georgia College of Public Health.

14 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012